Jan Stetka

7PUBLICATIONS
26CO-AUTHORS
Haematological tumoursMolecular targetsMetabolic medicinePredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 30, 2026
A single <i>JAK2</i>-V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non-conditioned recipient mice.

|Mar 17, 2024
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.

Marc Usart, Jan Stetka, Damien Luque Paz

|Jan 31, 2024
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.

Marc Usart, Nils Hansen, Jan Stetka

|Feb 09, 2023
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.

Jan Stetka, Marc Usart, Lucia Kubovcakova

|May 05, 2021
Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34<sup>+</sup> Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.

Pavla Koralkova, Monika Belickova, David Kundrat

|Apr 11, 2020
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.

Jan Stetka, Jan Gursky, Julie Liñan Velasquez

Pageof 2

Frequent Collaborators

4 joint publications

Radek C Skoda

3 joint publications

Pavla Vyhlidalova

3 joint publications

Marc Usart

2 joint publications

Vladimir Divoky